BACKGROUND: The Stanford group has reported excellent results with the Stanford V regimen for @entity1 with bulky and/or advanced @entity978 ( @entity978 ). However, Gobbi reported markedly inferior @entity177 ( @entity177 ) comparing Stanford V to other regimens but included major deviations from the original program. We retrospectively examined whether treatment at our institution carefully following Stanford V guidelines would confirm the original Stanford outcome data. @entity1 AND METHODS: From June 1995 to May 2002, 126 @entity1 with either locally extensive or advanced @entity978 were treated with the 12-week Stanford V chemotherapy program followed by 36-Gy involved-field radiotherapy to sites initially > or =5 cm and/or to macroscopic @entity4558 . Overall, 26% had stage IV disease and 20% had @entity3538 ( @entity3538 ) > or =4. @entity1349 ( @entity1349 ), disease-specific survival, progression-free survival (PFS), @entity177 , and freedom from second relapse (FF2R) were determined. RESULTS: The 5- and 7-year @entity1349 were 90% and 88%, respectively. The 5-year @entity177 was 78%. @entity3538 > or =4 was a significant independent predictor of worse @entity1349 and PFS. The FF2R was 64% at 3 years. CONCLUSION: Stanford V with appropriate radiotherapy is a highly effective regimen for locally extensive and advanced @entity978 .

Stanford V program for locally extensive and advanced XXXX : the Memorial Sloan-Kettering Cancer Center experience.

@entity1 :: ('9606', 'Species') :: ['patients', 'PATIENTS'] @entity3538 :: ('MESH:D002341', 'Disease') :: ['IPS', 'international prognostic score'] @entity4558 :: ('MESH:D013158', 'Disease') :: ['splenic disease'] @entity177 :: ('MESH:D051437', 'Disease') :: ['FFS', 'failure-free survival'] @entity978 :: ('MESH:D006689', 'Disease') :: ['HL', 'Hodgkin lymphoma'] @entity1349 :: ('MESH:D011475', 'Disease') :: ['OS', 'Overall survival']
@entity978 :: (MESH:D006689,Disease) :: ['Hodgkin lymphoma']
